Brief: Allergy Therapeutics Says Ordinary Shares To Be Suspended From Trading On AIM
Dec 15 (Reuters) - Allergy Therapeutics PLC AGY.L :
* ANNUAL REPORT AND ACCOUNTS DELAYED
* COMPANY'S ORDINARY SHARES WILL BE SUSPENDED FROM TRADING
ON AIM
WITH EFFECT FROM 7.30 A.M. ON 2 JANUARY 2024.
Source text for Eikon: ID:nRSO0237Xa
Further company coverage: AGY.L
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Allergy Therapeutics
See all newsBrief: Allergy Therapeutics Expects FY 2026 Revenue Of £59.90 Million, Up 9% Reported
UK's Allergy Therapeutics FY revenue beats on Grassmuno launch
Allergy Therapeutics - Trading update for the year ended 30 June 2026
Brief: Allergy Therapeutics Appoints Helge Weiner-Trapness As Executive Chairman
Allergy Therapeutics - Appointment of Executive Chairman